Holotype HLA Early Access Program Results: An “Uncontrolled” Study

Authors: Efi Melista, Krisztina Rigó, Szilveszter Juhos, György Horváth, Peter Meintjes, Tim Hague Abstract: NGS-based (Next Generation Sequencing) HLA typing can offer accurate and unambiguous genotyping results with minimal manual intervention, eliminating the requirement for reflexive testing. In a clinical setting an easy-to-follow protocol with minimal hands-on time is also...

 

Read more

Holotype HLA Now CE-IVD in Europe

Omixon announce today that Holotype HLA™ has been approved as a CE Marked IVD for sale in Europe, and will be available from April 2016 to all European customers as IVD, while remains RUO in the USA. Holotype HLA is the most globally recognized Next Generation Sequencing (NGS) Assay...

 

Read more

Omixon Holotype Early Access Program Featured at ASHI Annual Meeting 2015

Omixon announce today that Holotype HLA™ and other Omixon products will be featured in four oral presentations and 12 poster presentations at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Savannah, Georgia. Additionally, in the Tuesday Vendor Symposium, Omixon’s CEO, Tim Hague, will present extended...

 

Read more

Omixon Symposium at APHIA in Bangkok, Thailand

Join us for the upcoming Omixon Symposium, “Introduction to Holotype HLA™ and EAP Success“, our very first event at APHIA in Bangkok!   Date: Wednesday, October 14, 2015 Time: 1:00pm – 1:30pm ICT Venue: Mandarin Hotel, Bangkok Content Welcome & Introduction Presentation by Efi Melista & Marcello Scala Discussion,...

 

Read more